[
  {
    "ts": null,
    "headline": "Pharma Stocks Are Close to Breaking Out. Earnings Could Set Them Free.",
    "summary": "Pharmaceutical stocks just broke out to new highs—and earnings could push them even higher.  The  exchange-traded fund is up 32% in the past six months to almost $57.  Also helping the rally is that healthcare companies are investing in artificial intelligence to help them identify revenue opportunities with lower costs, potentially lifting profit margins.",
    "url": "https://finnhub.io/api/news?id=d680fcc926368f93c29c79205fee63d7f68d21e64787987f131581084144d6b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769622420,
      "headline": "Pharma Stocks Are Close to Breaking Out. Earnings Could Set Them Free.",
      "id": 138287497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks just broke out to new highs—and earnings could push them even higher.  The  exchange-traded fund is up 32% in the past six months to almost $57.  Also helping the rally is that healthcare companies are investing in artificial intelligence to help them identify revenue opportunities with lower costs, potentially lifting profit margins.",
      "url": "https://finnhub.io/api/news?id=d680fcc926368f93c29c79205fee63d7f68d21e64787987f131581084144d6b6"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Set to Report Q4 Earnings: What Investors Should Know",
    "summary": "AMGN stock is in focus ahead of Q4 earnings, with biosimilar pressure and newer drug growth shaping expectations for the quarter.",
    "url": "https://finnhub.io/api/news?id=5fb362265004804365297da010696e14caad47475b515f388ba8e129ad6026c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769617440,
      "headline": "Amgen Set to Report Q4 Earnings: What Investors Should Know",
      "id": 138285164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AMGN stock is in focus ahead of Q4 earnings, with biosimilar pressure and newer drug growth shaping expectations for the quarter.",
      "url": "https://finnhub.io/api/news?id=5fb362265004804365297da010696e14caad47475b515f388ba8e129ad6026c5"
    }
  },
  {
    "ts": null,
    "headline": "Thyroid Eye Disease Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035",
    "summary": "The global thyroid eye disease (TED) market is experiencing growth due to innovative treatment options, enhanced diagnostics, and increased awareness. TED, linked to hyperthyroidism, causes eye inflammation, leading to bulging and discomfort. Emerging therapies like monoclonal antibodies targeting the IGF-1 receptor are expanding treatment prospects. Significant drivers include advancements like Teprotumumab (Tepezza) and rising disease awareness. However, high treatment costs and limited infras",
    "url": "https://finnhub.io/api/news?id=8f1651576e5961e9faceb65396c98494620e1c83b59595aa6bd11ab9989e03bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769609640,
      "headline": "Thyroid Eye Disease Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035",
      "id": 138281543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The global thyroid eye disease (TED) market is experiencing growth due to innovative treatment options, enhanced diagnostics, and increased awareness. TED, linked to hyperthyroidism, causes eye inflammation, leading to bulging and discomfort. Emerging therapies like monoclonal antibodies targeting the IGF-1 receptor are expanding treatment prospects. Significant drivers include advancements like Teprotumumab (Tepezza) and rising disease awareness. However, high treatment costs and limited infras",
      "url": "https://finnhub.io/api/news?id=8f1651576e5961e9faceb65396c98494620e1c83b59595aa6bd11ab9989e03bb"
    }
  },
  {
    "ts": null,
    "headline": "TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026",
    "summary": "TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will highlight practical, scalable approaches to advancing more efficient, patient-centered clinical trials across the research lifecycle at SCOPE Summit 2026, taking place February 2-5 in Orlando, Florida.",
    "url": "https://finnhub.io/api/news?id=c1a992498f9bac0f92cd284cfde5062818544c1b6f16c27d4322f94e119479f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769607000,
      "headline": "TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026",
      "id": 138280643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will highlight practical, scalable approaches to advancing more efficient, patient-centered clinical trials across the research lifecycle at SCOPE Summit 2026, taking place February 2-5 in Orlando, Florida.",
      "url": "https://finnhub.io/api/news?id=c1a992498f9bac0f92cd284cfde5062818544c1b6f16c27d4322f94e119479f2"
    }
  },
  {
    "ts": null,
    "headline": "Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population",
    "summary": "The Global Glioma Market is focused on managing gliomas, aggressive brain tumors from glial cells. Glioblastoma Multiforme (GBM) is the deadliest type, characterized by rapid growth and invasiveness. Early diagnosis and treatment are crucial for improving patient outcomes. The market is driven by rising glioma cases, advancing cancer therapies, and enhanced diagnostic tools. Challenges include drug resistance, high treatment costs, and complex regulatory issues. Leading companies like Merck & Co",
    "url": "https://finnhub.io/api/news?id=be844d19e718dbc24b1c5f2029e9c25e198fe1cc276b66d02030ff0c0856a114",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769601840,
      "headline": "Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population",
      "id": 138280644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Global Glioma Market is focused on managing gliomas, aggressive brain tumors from glial cells. Glioblastoma Multiforme (GBM) is the deadliest type, characterized by rapid growth and invasiveness. Early diagnosis and treatment are crucial for improving patient outcomes. The market is driven by rising glioma cases, advancing cancer therapies, and enhanced diagnostic tools. Challenges include drug resistance, high treatment costs, and complex regulatory issues. Leading companies like Merck & Co",
      "url": "https://finnhub.io/api/news?id=be844d19e718dbc24b1c5f2029e9c25e198fe1cc276b66d02030ff0c0856a114"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Lawsuit Over 340B Discounts Puts Pricing And Policy In Focus",
    "summary": "Sagebrush Health Services has filed a lawsuit against Amgen, alleging unlawful termination of discounted drug sales under the 340B Drug Pricing Program. The complaint claims Amgen bypassed federal protocols and limited patient access to lower cost medications for underserved communities. The case raises questions around Amgen's compliance with federal discount rules and its approach to safety net healthcare providers. For investors watching Amgen (NasdaqGS: AMGN), this case arrives with the...",
    "url": "https://finnhub.io/api/news?id=1715292bda94aca53aab9f7404ed4cda84efc5387a43aab3032eb498218b69de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769587768,
      "headline": "Amgen Lawsuit Over 340B Discounts Puts Pricing And Policy In Focus",
      "id": 138279111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Sagebrush Health Services has filed a lawsuit against Amgen, alleging unlawful termination of discounted drug sales under the 340B Drug Pricing Program. The complaint claims Amgen bypassed federal protocols and limited patient access to lower cost medications for underserved communities. The case raises questions around Amgen's compliance with federal discount rules and its approach to safety net healthcare providers. For investors watching Amgen (NasdaqGS: AMGN), this case arrives with the...",
      "url": "https://finnhub.io/api/news?id=1715292bda94aca53aab9f7404ed4cda84efc5387a43aab3032eb498218b69de"
    }
  }
]